What is Indivior Pharmaceuticals, Inc. 's market cap?

Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.8B and trades on NASDAQ.

What is Indivior Pharmaceuticals, Inc. 's revenue and profitability?

Indivior Pharmaceuticals, Inc. generated $1.3B in trailing twelve-month revenue with net income of $251.0M, representing a net margin of 19.4%. Gross margin stands at 81.3%, with free cash flow of -$192.0M. These figures are based on the Q1 2026 filing.

Who are Indivior Pharmaceuticals, Inc. 's competitors?

Indivior Pharmaceuticals, Inc. 's key competitors include Alkermes, Collegium Pharmaceutical, Inc. Common Stock, Emergent Biosolutions, Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does Indivior Pharmaceuticals, Inc. have?

Indivior Pharmaceuticals, Inc. 's subsidiaries include Indivior U.K. Limited.

Where is Indivior Pharmaceuticals, Inc. headquartered?

Indivior Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 1,164 people. It has been publicly traded since 2014.

Indivior Pharmaceuticals, Inc.

INDV

Indivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses.

Market cap

$4.85B+123%

Revenue$1.3B+10.3%

Net income$251.0M+3,686%

Free cash flow-$192.0M-605%

EPS (diluted)$1.95+9,850%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$317.0MBeat by $44.2M EPS$0.96Beat by $0.32

Read the full report

Next report

Aug 4, 2026 (In 5 days)

Revenue estimate$307.6M

EPS estimate$0.92

Financials

Q1 2026

Income statement

See full

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Balance sheet

See full

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Cash flow

See full

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Valuation & ratios

Valuation

See full

Market cap$4.85B+123%

Enterprise value$5.18B+157%

P/E19.3×-0.7×

P/S3.8×+1.9×

Profitability

See full

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Returns & leverage

See full

Current ratio0.9×0.0×

Segments

By product

See full

SUBLOCADE$232.0M+31.8%

Sublingual & other$50.0M-7.4%

PERSERIS$5.0M+25.0%

By segment

See full

Reportable Segment$317.0M+19.2%

By geography

See full

Rest of World$45.0M+2.3%

Competitors

By market cap

Alkermes$8.5B+90.3%

JAN

Janus Living $6.7B—

Indivior Pharmaceuticals, Inc. $4.8B+125%

TRV

Trevi Therapeutics, Inc.$2.6B+185%

Collegium Pharmaceutical, Inc.$1.2B+16.1%

Emergent Biosolutions$377.2M+6.9%

Nutriband$35.9M-57.2%

Adial Pharmaceuticals$6.5M-32.5%

By revenue growth

JAN

Janus Living +43.6%

Collegium Pharmaceutical, Inc.+19.9%

Alkermes+10.8%

Indivior Pharmaceuticals, Inc. +10.3%

Emergent Biosolutions-29.9%

By net margin

Indivior Pharmaceuticals, Inc. 19.44%+20.0pp

Emergent Biosolutions9.62%+36.6pp

Collegium Pharmaceutical, Inc.9.41%+2.8pp

Alkermes3.97%-19.2pp

JAN

Janus Living -2,552.66%-2,506pp

Profile

Indivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses. The company focuses on addressing the opioid crisis through innovative long-acting injectable and transmucosal drug delivery technologies. Its value proposition is centered on providing treatment solutions that mitigate the risks of misuse and diversion while improving patient adherence.

Competitive position

A leading provider of buprenorphine-based treatments for opioid use disorder with a strong patent portfolio and specialized regulatory expertise in controlled substances.

GeographiesUnited States, Canada, Australia, European Union

Customer segmentsPatients with substance use disorders, Public and private insurers, Government health agencies

Business modelResearch and Development, Manufacturing, Intellectual Property Licensing

SuppliersActive pharmaceutical ingredient (API) suppliers, Contract manufacturing organizations, Specialized chemical suppliers

CustomersWholesale distributors, Retail pharmacies, Government health systems (Medicaid/Medicare), Correctional facilities

CountryUnited States of America

Listed2014

Employees1.2K

CEOJoseph J. Ciaffoni

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteindivior.com

FilingsSEC EDGAR

Ask your AI about Indivior Pharmaceuticals, Inc. .

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's market cap?: Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.8B and trades on NASDAQ.
What is Indivior Pharmaceuticals, Inc. 's revenue and profitability?: Indivior Pharmaceuticals, Inc. generated $1.3B in trailing twelve-month revenue with net income of $251.0M, representing a net margin of 19.4%. Gross margin stands at 81.3%, with free cash flow of -$192.0M. These figures are based on the Q1 2026 filing.
Who are Indivior Pharmaceuticals, Inc. 's competitors?: Indivior Pharmaceuticals, Inc. 's key competitors include Alkermes, Collegium Pharmaceutical, Inc. Common Stock, Emergent Biosolutions, Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Indivior Pharmaceuticals, Inc. have?: Indivior Pharmaceuticals, Inc. 's subsidiaries include Indivior U.K. Limited.
Where is Indivior Pharmaceuticals, Inc. headquartered?: Indivior Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 1,164 people. It has been publicly traded since 2014.